In this study, we evaluate the diagnostic values of Cytokeratin 19 fragment (CYFRA21‐1), Fibrin/fibrinogen degradation products (FDP) and CYFRA21‐1 + FDP in bladder cancer, with the objective to expand the application scope of urinary tumor markers in the diagnosis of bladder cancer. The gene discussed is KRT19; the disease is neoplasm.